Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C31H48O6.5H2O |
| Molecular Weight | 606.7856 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.[H][C@@]12C[C@@H](O)[C@@]3([H])[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@]4([H])CC[C@]3(C)[C@@]1(C)C[C@H](OC(C)=O)\C2=C(\CCC=C(C)C)C(O)=O
InChI
InChIKey=ILJWZIXNGJYXOL-KFEPNFQESA-N
InChI=1S/C31H48O6.5H2O/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32;;;;;/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36);5*1H2/b26-20-;;;;;/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-;;;;;/m0...../s1
Fusidic acid is a anti-bacterial agent, initially isolated from Fusidium coccineum by Godtfredsen et al (Leo Pharma) in 1960. It is discussed that fusidic acid exerts its anti-microbial effect by inhibiting bacterial elongation factor G, thus suppressing the protein synthesis. Fusidic acid is widely used in Europe under the names Fucidin H(fusidic acid / hydrocortisone acetate), Fucidin (fusidic acid / sodium fusidate) and Fucicort (fusidic acid / betamethasone valerate) for the treatment of primary/secondary skin infections and inflammatory dermatoses.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Bacterial elongation factor G |
1.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | FUCIDIN Approved UseFor use in the treatment of primary and secondary skin infections caused by sensitive strains of Staphylococcus aureus, Streptococcusspp and Corynebacterium minutissimum. Primary skin infections that may be expected to respond to treatment with FUCIDIN OINTMENT (sodium fusidate) and CREAM (fusidic acid) include: impetigo contagiosa, erythrasma and secondary skin infections such as infected wounds and infected burns. |
|||
| Curative | FUCICORT Approved UseFUCICORT is indicated in inflammatory dermatoses where bacterial infection is present or likely to occur. Inflammatory dermatoses include atopic eczema, discoid eczema, seborrheic dermatitis, contact dermatitis, lichen simplex chronicus, psoriasis, discoid lupus erythematosus |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Protein synthesis in Mycobacterium tuberculosis H37Rv and the effect of streptomycin in streptomycin-susceptible and -resistant strains. | 1973 Sep |
|
| Suppression of HIV replication in vitro by fusidic acid parallels cell toxicity. | 1989 Jan |
|
| Susceptibility of mycobacteria to fusidic acid. | 1990 Apr |
|
| Anti-HIV activity of dideoxynucleosides, foscarnet and fusidic acid is potentiated by human leukocyte interferon in blood-derived macrophages. | 1994 May-Jun |
|
| Acute renal failure in association with fusidic acid. | 1997 Jun |
|
| A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014 Jan |
Patents
Sample Use Guides
A small amount of fucidin ointment(sodium fusidate) or cream (fusidic acid) should be
applied to the lesion 3 or 4 times daily until favourable results are achieved. Futicort cream (fusidic acid / betamethasone valerate) is applied 2 times daily.
Route of Administration:
Topical
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000087312
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY | |||
|
SUB20997
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY | |||
|
7EB01222KN
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY | |||
|
76957416
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
